This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors

PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors (PARs)
Inside activation of EGFR by PAR as indicated by Tyr-phosphorylation, potently inhibited by Pc(4-4). Credit: Oncoscience (2024). DOI: 10.18632/oncoscience.599

A new editorial paper was published in Oncoscience, titled "PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs."

While targeted cancer therapy is greatly dependent on specific oncogenic pathways or conferred by genetic alterations, it remains challenging and somewhat disappointing. The high level of failure relies on the interplay between the dose for desired therapy versus toxicity, namely the therapeutic index. Furthermore, one should take into consideration resistance response that develops with time to a given drug, contributing immensely to the given drawback.

In this new editorial, researchers Jeetendra Kumar Nag, Amnon Hoffman, Chaim Gilon, Beatrice Uziely, and Rachel Bar-Shavit from Hadassah-Hebrew University Medical Center and The Hebrew University highlight the need for alternative targeting routes.

"Although the contribution of G-protein-coupled receptors (GPCRs) in cancer malignancy is growing, GPCR-based therapies are rare," write the researchers.

Credit: Impact Journals LLC

Importantly, GPCRs are involved in many aspects of tumorigenesis, including proliferation, invasion, survival at secondary sites, cancer stemness and cancer associated signaling pathways. Indeed, big data population analyses indicate the significance of GPCRs as valuable targets for therapy in cancer. Protease activated receptors (PARs), a subgroup of GPCRs, form a family of four members; PAR1-4.

"TCGA and GTEx database show that PAR2/F2RL1 is significantly overexpressed in many types of epithelial malignancies among of which are colon, breast and ovarian cancers," conclude the authors.

More information: Jeetendra Kumar Nag et al, PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs, Oncoscience (2024). DOI: 10.18632/oncoscience.599

Provided by Impact Journals LLC
Citation: PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors (2024, May 24) retrieved 16 June 2024 from https://medicalxpress.com/news/2024-05-ph-motifs-platform-drug-lessons.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

G-protein coupled receptor findings could accelerate research and development of new cancer treatments

0 shares

Feedback to editors